Neurocrine raises 2026 INGREZZA sales guidance to $2.825B-$2.875B while integrating VYKAT XR (NASDAQ:NBIX)
· seekingalpha.com
Neurocrine (NBIX) Q2 2026 earnings call: $950M+ sales, raised INGREZZA guidance, VYKAT XR integration, 2027 catalysts—read key takeaways.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...